Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 29, 2017

Auckland UniServices to supply cytisine for Achieve’s RAUORA trial

US-based pharmaceutical firm Achieve Life Sciences has signed a clinical trial supply and cooperation agreement with the University of Auckland in New Zealand to assess cytisine for smoking cessation.

US-based pharmaceutical firm Achieve Life Sciences has signed a clinical trial supply and cooperation agreement with the University of Auckland in New Zealand to assess cytisine for smoking cessation.

Cytisine is a plant-based alkaloid with a high affinity for binding to the nicotinic acetylcholine receptor.

Under the terms of the agreement, the university’s commercial arm Auckland UniServices will provide the investigational candidate for use in Achieve’s Phase III RAUORA clinical trial.

The investigator-sponsored and led, single-blind, randomised, non-inferiority trial will assess the safety, efficacy and cost-effectiveness of cytisine in 2,140 Māori (indigenous New Zealanders) and whānau (family) of Māori subjects when compared to varenicline.

RAUORA is being conducted by the university in collaboration with the Lakes District Health Board and Brunel University London, with funding from the Health Research Council of New Zealand.

“This trial is well-aligned with our mission at Achieve, which is to bring cytisine forward as a new treatment option around the globe.”

Achieve Life Sciences chairman and CEO Rick Stewart said: “We are pleased to contribute cytisine to this important initiative to help improve the health and well-being of Māori and their whānau.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“This trial is well-aligned with our mission at Achieve, which is to bring cytisine forward as a new treatment option around the globe to help the millions of smokers who are battling nicotine and tobacco addiction.”

The Phase III trial will compare quit rates at six months and expects that cytisine treatment in combination with behavioural support for 12 weeks will be similar to the effectiveness of 12 weeks of varenicline and behavioural support.

Achieve previously evaluated cytisine in two large-scale Phase III trials with a total of 2,000 patients and plans to initiate another Phase III trial mid-next year in the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU